T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amazon
AMZN
|
+$3.11B |
| 2 |
Meta Platforms (Facebook)
META
|
+$2.59B |
| 3 |
EQT Corp
EQT
|
+$1.31B |
| 4 |
Colgate-Palmolive
CL
|
+$1.08B |
| 5 |
Adobe
ADBE
|
+$1.06B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$1.92B |
| 2 |
UnitedHealth
UNH
|
+$1.78B |
| 3 |
Advanced Micro Devices
AMD
|
+$1.55B |
| 4 |
Ross Stores
ROST
|
+$1.54B |
| 5 |
ASML
ASML
|
+$1.49B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 31.61% |
| 2 | Healthcare | 16.91% |
| 3 | Consumer Discretionary | 11.05% |
| 4 | Financials | 10.6% |
| 5 | Communication Services | 9.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
576
CACI
CACI
$14.9B
| $80.5M | 0.01% |
236,091
-3,954
| -2% | -$1.23M |
|
577
Curtiss-Wright
CW
$25.8B
| $79.7M | 0.01% |
433,931
+23,366
| +6% | +$3.98M |
|
578
Ford
F
$55.2B
| $79.3M | 0.01% |
5,243,083
-22,312
| -0.4% | -$282K |
|
|
NARI
579
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $79M | 0.01% |
1,359,337
-504,479
| -27% | -$31.8M |
|
580
Atkore
ATKR
$3.17B
| $79M | 0.01% |
506,322
-64,631
| -11% | -$8.47M |
|
581
Xencor
XNCR
$1.7B
| $78.9M | 0.01% |
3,158,576
-130,313
| -4% | -$3.55M |
|
582
Medpace
MEDP
$16.4B
| $78.1M | 0.01% |
325,116
-1,895
| -0.6% | -$394K |
|
583
Ecolab
ECL
$77.3B
| $78M | 0.01% |
418,025
-5,365
| -1% | -$923K |
|
584
Texas Roadhouse
TXRH
$13.8B
| $77.9M | 0.01% |
693,973
-4,254
| -0.6% | -$468K |
|
585
UFP Industries
UFPI
$5.05B
| $76.9M | 0.01% |
792,752
+24,597
| +3% | +$2.05M |
|
586
Edwards Lifesciences
EW
$53.3B
| $76.7M | 0.01% |
813,405
-18,108
| -2% | -$1.57M |
|
587
Shoals Technologies Group
SHLS
$1.4B
| $76.7M | 0.01% |
3,001,718
+231,302
| +8% | +$5.35M |
|
588
Zentalis Pharmaceuticals
ZNTL
$304M
| $75.7M | 0.01% |
2,684,352
+484,183
| +22% | +$11.6M |
|
589
West Fraser Timber
WFG
$5.51B
| $75.7M | 0.01% |
879,983
+183,346
| +26% | +$13.8M |
|
590
CDW
CDW
$17.3B
| $75.6M | 0.01% |
412,128
-21,012
| -5% | -$3.67M |
|
591
Murphy USA
MUSA
$10.2B
| $75.1M | 0.01% |
241,494
-2,093
| -0.9% | -$586K |
|
592
Iridium Communications
IRDM
$5.32B
| $74.6M | 0.01% |
1,200,538
+20,061
| +2% | +$1.24M |
|
593
Incyte
INCY
$24.4B
| $74.4M | 0.01% |
1,195,753
-622,594
| -34% | -$41.6M |
|
594
Sanofi
SNY
$105B
| $74.3M | 0.01% |
1,378,928
-664,489
| -33% | -$35.8M |
|
|
RNAM
595
DELISTED
Avidity Biosciences
RNAM
| $74.1M | 0.01% |
6,684,241
-180,144
| -3% | -$2.26M |
|
596
UiPath
PATH
$8B
| $73.8M | 0.01% |
4,452,706
+977,918
| +28% | +$15.7M |
|
597
Structure Therapeutics
GPCR
$3.85B
| $73.7M | 0.01% |
1,773,350
+986,845
| +125% | +$27.7M |
|
598
Ameriprise Financial
AMP
$49.9B
| $73.6M | 0.01% |
221,509
-95
| -0% | -$29.2K |
|
599
Watsco Inc
WSO
$12.9B
| $73.4M | 0.01% |
192,397
-104
| -0.1% | -$35.3K |
|
600
Gaming and Leisure Properties
GLPI
$12.7B
| $73.3M | 0.01% |
1,511,934
+162,380
| +12% | +$8.1M |
|
Similar funds
T. Rowe Price Associates's Q2 2023 Portfolio in Review
As of Q2 2023, T. Rowe Price Associates held 3,044 positions worth $718B, up 7.4% from $668B the previous quarter. Its ten largest holdings account for 32% of the portfolio.
T. Rowe Price Associates's Q2 2023 filing shows 123 new, 1,636 increased, 968 reduced and 150 closed positions. Its largest new stake was Kenvue: 26,317,608 shares worth $695M. The largest sale was Microsoft, an estimated $1.92B.
By sector, the portfolio is most concentrated in Technology at 32% of assets, up from 30% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2023 buy was Kenvue: 26,317,608 shares worth $695M.
- T. Rowe Price Associates added most to Amazon in Q2 2023, an estimated $3.11B increase.
- T. Rowe Price Associates's biggest Q2 2023 reduction was Microsoft, cutting an estimated $1.92B.
- T. Rowe Price Associates fully exited Canadian Natural Resources in Q2 2023, selling an estimated $112M.
- T. Rowe Price Associates's ten largest holdings make up 32% of its $718B portfolio in Q2 2023.
- T. Rowe Price Associates opened 123 new positions and closed 150 in Q2 2023.
- T. Rowe Price Associates's portfolio value rose 7.4% quarter-over-quarter to $718B.
Based on T. Rowe Price Associates's 13F filing for Q2 2023, filed 14 Aug 2023.